In the BioHarmony Drug Report Database
Vildagliptin
Galvus, Jalra, Xiliarx (vildagliptin) is a small molecule pharmaceutical. Vildagliptin was first approved as Galvus on 2007-09-25. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4.
Trade Name
|
Galvus, Jalra, Xiliarx |
|---|---|
Common Name
|
vildagliptin |
ChEMBL ID
|
CHEMBL142703 |
Indication
|
type 2 diabetes mellitus |
Drug Class
|
Dipeptidyl aminopeptidase-IV inhibitors |
Image (chem structure or protein)